Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS) | MicrobiomeTrials← Back to trialsNCT05089084
Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)
CompletedPHASE3INTERVENTIONAL
Trial Details
Start: 2021-12-14Est. Completion: 2024-04-29
Enrollment target: 75 participants Locations- Clinical Site 1, Boca Raton, Florida, United States
- Clinical Site 2, Suwanee, Georgia, United States
- Clinical Site 3, Indianapolis, Indiana, United States
- Clinical Site 4, Elkridge, Maryland, United States
- Clinical Site 5, St Louis, Missouri, United States
- Clinical Site 7, New York, New York, United States
- Clinical Site 6, New York, New York, United States
- Clinical Site 8, Austin, Texas, United States
- Clinical Site 9, Norfolk, Virginia, United States
- Clinical Site 10, Córdoba, Argentina
- Clinical Site 11, Formosa, Argentina
- Clinical Site 14, Camperdown, New South Wales, Australia
- Clinical Site 15, St Leonards, New South Wales, Australia
- Clinical Site 16, Melbourne, Victoria, Australia
- Clinical Site 12, Melbourne, Australia
- Clinical Site 13, Nedlands, Australia
- Clinical Site 17, Graz, Austria
- Clinical Site 18, Edegem, Belgium
- Clinical Site 19, Ghent, Belgium
Other microbiome trials you might be interested in
Type 1 Hyperlipoprotenemia
Type I hyperlipoproteinemia (T1HLP, also known as familial chylomicronemia syndrome or FCS) is a rare diseasewhere the b…
Dallas, United StatesEst. completion Aug 1, 2027
Familial ChylomicronemiaHigh Risk Severe Hypertriglyceridemia (SHTG)
This is a treatment program for the use of plozasiran in adults (AROAPOC3-EAP-002) and adolescents (AROAPOC3-EAP-003) wi…
Pasadena, United States
Clinical Site 20, Leuven, BelgiumClinical Site 21, Liège, BelgiumClinical Site 22, London, Ontario, CanadaClinical Site 23, Toronto, Ontario, CanadaClinical Site 24, Chicoutimi, Quebec, CanadaClinical Site 25, Montreal, Quebec, CanadaClinical Site 26, Québec, Quebec, CanadaClinical Site 27, Zagreb, CroatiaClinical Site 29, Marseille, Cedez 05, FranceClinical Site 28, Paris, FranceClinical Site 30, Jena, GermanyClinical Site 31, Leipzig, GermanyClinical Site 32, Galway, IrelandClinical Site 33, Jerusalem, IsraelClinical Site 34, Chiba, JapanClinical Site 35, Ishikawa, JapanClinical Site 36, Osaka, JapanClinical Site 37, Tochigi, JapanClinical Site 38, Tokyo, JapanClinical Site 39, Tokyo, JapanClinical Site 41, Tlalpan, Mexico DF, MexicoClinical Site 42, Cuernavaca, Morelos, MexicoClinical Site 40, Mexico City, MexicoClinical Site 44, Auckland, New ZealandClinical Site 43, Auckland, New ZealandClinical Site 45, Christchurch, New ZealandClinical Site 46, Muscat, OmanClinical Site 47, Lodz, PolandClinical Site 48, Belgrade, SerbiaClinical Site 49, Niš, SerbiaClinical Site 50, Singapore, SingaporeClinical Site 51, Gwangju, South KoreaClinical Site 52, Seoul, South KoreaClinical Site 53, A Coruña, SpainClinical Site 54, Granada, SpainClinical Site 55, Madrid, SpainClinical Site 56, Santiago de Compostela, SpainClinical Site 58, Melikgazi, Kayseri, Turkey (Türkiye)Clinical Site 57, Izmir, Turkey (Türkiye)